在COVID-19的后急性后果的三年结果
Miao Cai1,2, Yan Xie1,2,3, Eric J Topol4
1Clinical Epidemiology Center, Research and Development Service, VA St. Louis Health Care System, St. Louis, MO, USA.
长期的COVID-19 (冠状病毒疾病2019) 后续,或COVID-19 (PASC) 后急性后续,在三年内显示风险下降. 然而,住院患者在感染后的第三年仍面临高死亡率和严重健康损失.
科学领域:
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2) 可以导致长期的健康问题,称为COVID-19 (PASC) 后急性后续.
- 之前的研究描述了PASC风险在感染后长达两年的风险,但长期数据有限.
研究的目的:
- 评估SARS-CoV-2感染后长达三年的死亡率和PASC的长期风险.
- 为了比较住院和非住院个体之间的这些风险.
主要方法:
- 通过美国退伍军人事务部的数据进行了一项大型队列研究.
- 包括135,161名感染SARS-CoV-2的个体和5,206,835名对照,进行了三年的跟踪.
- 估计的死亡和事故风险PASC,计算残疾调整寿命年 (DALYs).
主要成果:
- 对于未住院的个人,过度死亡风险在一年后消失,PASC风险下降但仍然存在.
- 在住院患者中,死亡风险降低,但在第三年仍然显著增加 (IRR:1.29).
- 在住院患者中,PASC的大量残留风险在第三年仍然存在,这有助于显著的DALYs.
结论:
- 虽然死亡和PASC的风险在SARS-CoV-2感染后的三年内通常会降低,但住院患者仍然承受着重大负担.
- 住院患者在感染后的第三年面临着持续的高死亡率和严重的健康损失.
更多相关视频
08:38Three-dimensional Navigation-guided, Prone, Single-position, Lateral Lumbar Interbody Fusion Technique
Published on: July 15, 2021
08:13Development and Implementation of a Multi-Disciplinary Technology Enhanced Care Pathway for Youth and Adults with Concussion
Published on: January 20, 2019
相关概念视频
Pneumonia III: Complications and Assessment
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Acute Respiratory Failure-III
Classification of Illness
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology
